Intellia Therapeutics Wins China CRISPR Patent

GEN News Highlights, 19 June 2017,

Intellia Therapeutics, founded by Jennifer Doudna, has been awarded a broad patent for the CRISPR/Cas9 single guide gene editing system.  Intellia has licensed the CRISPR technology developed by Jennifer Doudna at the University of California-Berkeley. This latest announcement comes on the tails of the European Patent Office’s announcement favoring UC-Berkeley as well.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply